The BPC-157 TB-500 stack has earned its nickname, the "Wolverine Stack", for good reason. These two peptides target tissue repair through completely different biological pathways, and combining them has become one of the most talked-about recovery protocols in sports medicine and wellness circles heading into 2026.
But popularity doesn't equal clarity. Dosage recommendations vary wildly across forums, clinics, and online guides. Some protocols call for daily injections, others twice weekly. Some suggest 4-week cycles, others stretch to 8. For anyone trying to piece together a reliable BPC-157 TB-500 stack dosage protocol within the broader category of peptides for recovery, the signal-to-noise ratio is rough.
This guide cuts through the confusion. It covers the science behind each peptide, evidence-based dosing ranges, a practical week-by-week protocol, reconstitution and injection technique, side effects, and who this stack is, and isn't, appropriate for. All of it grounded in the available preclinical data and established practitioner protocols.
One critical disclaimer upfront: neither BPC-157 nor TB-500 has completed Phase 2/3 human clinical trials. Evidence is preclinical. Nothing here constitutes medical advice. Consult a qualified physician before starting any peptide protocol.
What BPC-157 and TB-500 Do — And Why Stacking Them Accelerates Recovery
BPC-157 (Body Protection Compound-157) is a synthetic peptide derived from a protein found in human gastric juice. It works primarily through VEGF (vascular endothelial growth factor) and nitric oxide (NO) pathways, promoting localized tissue repair. Animal studies show accelerated healing of tendons, ligaments, muscle, bone, and GI mucosa — though understanding the BPC-157 side effects is essential before starting.
The key genes involved: VEGFA (vascular growth), NOS3 (nitric oxide synthase for vascular repair), and COL1A1 (collagen Type I production). BPC-157's strength is site-specific, inject near an injured tendon, and the repair signals concentrate there.
TB-500 (Thymosin Beta-4 fragment) operates differently. It promotes cell migration through actin dynamics and stimulates angiogenesis (new blood vessel formation) systemically. The relevant genes include TMSB4X (Thymosin Beta-4), ACTA2 (actin regulation), and VEGFA.
Originally studied in equine medicine for racehorse tissue repair, TB-500 gained traction after Phase 2 trials on the parent compound (Thymosin Beta-4) showed accelerated corneal wound healing in humans.
Why the Stack Works
The logic is straightforward:
- BPC-157 = local repair (inject near injury site)
- TB-500 = systemic repair (works throughout the body)
- Combined = both localized and whole-body healing pathways activated simultaneously
They don't compete for the same receptors. BPC-157 upregulates VEGF and NO. TB-500 sequesters G-actin to drive cell migration. Different mechanisms, complementary results.
For someone dealing with multiple injury sites, chronic tendon issues, or post-surgical recovery, the BPC-157 TB-500 stack addresses repair from two angles that a single peptide can't match alone. That's why practitioners and athletes have gravitated toward this combination, even ahead of controlled combination studies being published.
Recommended Dosages for the BPC-157 TB-500 Stack
No FDA-approved dosages exist for either peptide (for standalone BPC-157 protocols, see the BPC-157 dosage guide). The ranges below come from established practitioner protocols, preclinical research extrapolations, and the 2026 edition of ThePeptideList's protocol guide.
BPC-157 Dosing
- Standard dose: 250–500 mcg per injection
- Frequency: Twice daily (morning + evening, approximately 12 hours apart)
- Route: Subcutaneous injection, preferably near the injury site for localized effect
- Estimated half-life: ~4 hours, which is why twice-daily dosing is standard
For GI-specific applications (gut lining support), oral BPC-157 in capsule form has been studied, though a Phase 1 trial found no quantifiable BPC-157 in plasma after oral dosing, raising bioavailability questions.
TB-500 Dosing
- Loading phase: 750 mcg twice weekly for 4 weeks
- Maintenance phase: 750 mcg once weekly
- Route: Subcutaneous (systemic effect, injection site doesn't need to be near the injury)
- Half-life: Unknown (peptide fragment)
Combined Stack Dosages
When running the BPC-157 TB-500 stack dosage protocol together:
| Peptide | Dose | Frequency | Duration |
|---|---|---|---|
| BPC-157 | 250–500 mcg | 2x daily | 4–6 weeks |
| TB-500 | 750 mcg | 2x weekly (loading) → 1x weekly (maintenance) | 4–8 weeks |
Most practitioners start BPC-157 at the lower end (250 mcg twice daily) and assess tolerance before increasing. TB-500 stays consistent at 750 mcg per injection throughout.
Body weight adjustments aren't well-established in the literature, but some clinics scale BPC-157 slightly higher (up to 500 mcg 2x daily) for individuals over 200 lbs. Platforms like Peptide Injections can connect patients with board-certified physicians who personalize these protocols based on individual factors.
Week-by-Week Protocol: Cycling, Timing, and Administration
Cycling matters. Running peptides indefinitely without breaks can reduce receptor sensitivity and increase unknown long-term risks. Here's a practical week-by-week breakdown.
Weeks 1–4: Loading Phase
- BPC-157: 250–500 mcg subcutaneous, twice daily (AM + PM)
- TB-500: 750 mcg subcutaneous, twice weekly (e.g., Monday and Thursday)
- Focus: Establish tissue repair response. Most users report noticeable changes in pain and mobility by week 2–3.
Weeks 5–6 (or 5–8): Maintenance Phase
- BPC-157: Continue at same dose, twice daily
- TB-500: Reduce to 750 mcg once weekly
- Focus: Sustain healing. Reassess injury status. Some practitioners extend this phase to 8 weeks for chronic injuries.
Post-Cycle: Off Period
- Minimum 2–4 weeks off both peptides
- Monitor symptom progression
- Repeat cycle if needed after the break
Timing Considerations
BPC-157 injections work best spaced ~12 hours apart, for example, 7 AM and 7 PM. Inject on an empty stomach or at least 30 minutes before eating for optimal absorption.
TB-500 timing is more flexible due to its systemic action. Many users inject in the morning on their designated days. There's no strict fasting requirement, though some practitioners recommend it.
Can you inject both on the same day? Yes. They can be drawn into the same syringe if both are reconstituted at compatible concentrations, though using separate syringes is simpler and reduces contamination risk.
Mid-Cycle Check-In
At the 4-week mark, baseline bloodwork should be repeated:
- CBC with differential
- CMP (liver and kidney function)
No specific biomarker tracks BPC-157 or TB-500 directly. Monitoring is symptom-based, track pain levels, range of motion, and functional improvement weekly.
Reconstitution, Injection Technique, and Storage Best Practices
Both BPC-157 and TB-500 arrive as lyophilized (freeze-dried) powder in vials. They must be reconstituted before use.
Reconstitution Steps
- Gather supplies: Bacteriostatic water (BAC water), alcohol swabs, insulin syringes (29–31 gauge)
- Clean the vial tops with alcohol swabs
- Draw bacteriostatic water into the syringe, typically 1–2 mL per vial, depending on desired concentration
- Inject BAC water into the vial by aiming the stream against the glass wall, not directly onto the powder
- Swirl gently. Never shake. Shaking can denature the peptide and destroy its effectiveness.
- Wait until fully dissolved (usually 1–2 minutes)
Calculating Your Dose
Example: A 5 mg BPC-157 vial reconstituted with 2 mL BAC water = 2,500 mcg per mL. For a 250 mcg dose, draw 0.1 mL (or 10 units on an insulin syringe).
For a 10 mg TB-500 vial with 2 mL BAC water = 5,000 mcg per mL. A 750 mcg dose = 0.15 mL (15 units).
Write these calculations down and tape them to the vial. Dosing errors are the most common mistake in peptide self-administration.
Injection Technique
BPC-157: Subcutaneous injection near the injury site when possible. Pinch the skin, insert the needle at a 45-degree angle, inject slowly, and release.
TB-500: Subcutaneous injection in the abdominal area (lower belly fat) is standard. Site doesn't matter since TB-500 acts systemically.
Rotate injection sites to avoid scar tissue buildup.
Storage Rules
- Unreconstituted powder: Room temperature is acceptable short-term, but refrigeration (2–8°C) extends shelf life
- Reconstituted BPC-157: Refrigerate. Use within 4 weeks
- Reconstituted TB-500: Refrigerate. Use within 4 weeks
- Never freeze reconstituted peptides
- Keep away from light, store in original packaging or wrap vials
If the solution appears cloudy or has particles after reconstitution, discard it. Peptide integrity matters.
Side Effects, Safety Considerations, and When to Seek Medical Guidance
Both peptides are generally reported as well-tolerated based on available preclinical data and anecdotal evidence. But "generally well-tolerated" isn't the same as "proven safe."
Common Side Effects
BPC-157:
- Injection site irritation
- Mild nausea (rare)
- Headache (rare)
TB-500:
- Injection site irritation
- Headache (rare)
- Mild fatigue
Most side effects are transient and resolve within hours. Persistent reactions warrant stopping the protocol and consulting a physician.
Serious Safety Considerations
The biggest concern with both peptides is their angiogenic potential, they promote new blood vessel formation. This is exactly what makes them effective for healing. But in someone with active cancer or undiagnosed tumors, promoting blood vessel growth could theoretically accelerate tumor development.
Also, TB-500 works through actin polymerization, which is involved in cell migration. The concern: this mechanism could theoretically promote tumor cell migration in cancer patients.
No long-term human safety data exists for either peptide. This is the fundamental limitation.
When to Seek Medical Guidance
Stop the protocol and contact a healthcare provider if:
- Severe injection site reactions (spreading redness, swelling, warmth)
- Persistent headaches or fatigue beyond 48 hours
- Any signs of allergic reaction (hives, difficulty breathing, swelling)
- Unexpected symptoms not attributable to other factors
Baseline Bloodwork
Before starting the BPC-157 TB-500 stack, get:
- CBC with differential, baseline immune and blood cell status
- CMP (comprehensive metabolic panel), liver and kidney function
- Repeat at 4 weeks to catch any changes early
Working with a physician who understands peptide therapy ensures proper monitoring. Peptide Injections matches patients with specialized providers in about 2 minutes, which removes the guesswork of finding a qualified practitioner.
Who Should (and Shouldn't) Use the BPC-157 TB-500 Stack
Best Candidates
The BPC-157 TB-500 stack fits specific recovery profiles:
- Athletes with recurring or multiple injuries, the systemic + local repair combination covers more ground than either peptide alone
- Post-surgical recovery patients, particularly after orthopedic procedures involving tendons, ligaments, or soft tissue
- Chronic injury patterns, individuals who've dealt with slow-healing tendon or ligament issues for months or years
- Cardiac repair support, TB-500's parent compound (Thymosin Beta-4) showed promise in animal models for post-myocardial infarction repair
- Hair regrowth protocols, TB-500 animal data includes accelerated hair regrowth, often combined with other therapies
The ideal user accepts the evidence limitations (preclinical, Grade D), is willing to work with a physician, and commits to proper bloodwork monitoring.
Who Should Avoid This Stack
- Active cancer patients, angiogenic and cell migration properties make this a clear contraindication
- Pregnant or breastfeeding individuals, zero safety data in this population
- Anyone under 18, developing bodies shouldn't be exposed to exogenous peptides without exceptional medical justification
- People expecting pharmaceutical-grade evidence, if you need completed human RCTs before trying something, this stack isn't there yet
- Those on unknown medication interactions, no interaction studies exist: disclose all medications to your provider
A Note on Genetics
Individual response varies. People with high endogenous Thymosin Beta-4 production (related to TMSB4X expression levels) may see diminished returns from exogenous TB-500. Similarly, NOS3 G894T carriers may experience slower BPC-157 response due to impaired nitric oxide-mediated healing.
Genetic testing isn't required but can help set realistic expectations. Some peptide therapy providers now offer pharmacogenomic assessments as part of their intake process.
The Single-Injury Question
If someone has one localized injury, a single torn ligament or inflamed tendon, BPC-157 alone may be sufficient. The stack shines when repair needs are systemic, multi-site, or chronic. Adding TB-500 to a single-injury protocol isn't harmful, but it may be unnecessary overhead.
Conclusion
The BPC-157 TB-500 stack dosage protocol combines two peptides with complementary repair mechanisms, local healing from BPC-157 and systemic repair from TB-500. The standard approach is BPC-157 at 250–500 mcg twice daily alongside TB-500 at 750 mcg twice weekly during loading, dropping to once weekly for maintenance, across a 4–8 week cycle.
The evidence is preclinical. The popularity is real. And the gap between the two is something every user needs to acknowledge.
Proper reconstitution, consistent injection technique, baseline bloodwork, and physician oversight aren't optional extras, they're foundational. For those looking to connect with a qualified peptide therapy provider quickly, Peptide Injections offers AI-powered matching with board-certified physicians in about 2 minutes.
Do the assignments. Get the bloodwork. Work with a professional. That's how the Wolverine Stack gets used responsibly.
Frequently Asked Questions About BPC-157 TB-500 Stack Dosage Protocol
What is the BPC-157 TB-500 stack dosage protocol and why is it called the Wolverine Stack?
The BPC-157 TB-500 stack combines two peptides with complementary repair mechanisms: BPC-157 for localized tissue healing and TB-500 for systemic repair. Called the 'Wolverine Stack' because it targets tissue repair through different biological pathways—VEGF/nitric oxide (BPC) and actin dynamics (TB)—accelerating recovery when used together.
What are the recommended dosages for BPC-157 and TB-500 in the stack protocol?
Standard BPC-157 dosing: 250–500 mcg twice daily subcutaneously. TB-500 dosing: 750 mcg twice weekly for the first 4 weeks (loading), then 750 mcg once weekly for maintenance. Both peptides are typically cycled for 4–8 weeks, followed by a 2–4 week off-period to maintain receptor sensitivity.
How should I reconstitute BPC-157 and TB-500 peptide powder before injection?
Dissolve lyophilized powder with bacteriostatic water (typically 1–2 mL per vial). Clean the vial with an alcohol swab, inject water against the glass wall (not directly onto powder), then gently swirl until fully dissolved. Never shake. Calculate your dose accurately—for example, 5 mg BPC in 2 mL water = 2,500 mcg per mL. Refrigerate after reconstitution; use within 4 weeks.
Can I take BPC-157 or TB-500 if I have active cancer or am pregnant?
No. Both peptides are contraindicated in active cancer due to their angiogenic (blood vessel-promoting) and cell migration properties, which could theoretically accelerate tumor growth. Zero safety data exists for pregnant or breastfeeding individuals. Always consult a qualified physician before starting any peptide protocol.
What bloodwork should I get before and during a BPC-157 TB-500 stack protocol?
Baseline bloodwork should include a CBC with differential and CMP (comprehensive metabolic panel) to assess immune and liver/kidney function. Repeat at the 4-week mark. No specific biomarkers directly track these peptides; monitoring is symptom-based—track pain levels, range of motion, and functional improvement weekly.
What are the common side effects of the BPC-157 TB-500 stack, and when should I seek medical guidance?
Most common side effects are transient: injection site irritation, mild nausea, or rare headaches. Stop the protocol and contact a healthcare provider if you experience severe injection site reactions, persistent headaches beyond 48 hours, or signs of allergic reaction. The primary safety concern is the angiogenic potential—promoting blood vessel formation—which contraindicates use in cancer patients.